TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Trimodal Prehabilitation Strategy on Perioperative Functional Capability and Prognosis of Patients Undergoing Thoracoscopic Lobectomy for Lung Cancer：a Randomized Controlled Trail
Brief Summary: The process of enhancing an individual's functional capacity to optimize physiologic reserves before an operation to withstand the stress of surgery has been coined prehabilitation. This is a prospective randomized controlled trail, designed to explore if the patients who take thoracoscopic lobectomy for lung cancer will benefit from family trimodal prehabilitation strategy. Trimodal prehabilitation includes exercise, nutrition supplement and physiology management preoperatively. It starts from the day that patients decide to take the surgery until the day before surgery, lasting 2\~3 week in our hospital. And we follow-up patients until 8 weeks after surgery to investigate if trimodal prehabilitation strategy can improve the postoperative functional recovery，reduce complications and improve prognosis.


Options:
A: Arm Label: Prehabilitation Plus; Type: ACTIVE_COMPARATOR; Interventions: Other: Prehabilitation Plus | Arm Label: Rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prehabilitation Plus; Assigned to Arm(s): Prehabilitation Plus
B: Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): N/A
C: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group
D: Arm Label: Prehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Trimodal prehabilitation management | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trimodal prehabilitation management; Assigned to Arm(s): Prehabilitation group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Trimodal Prehabilitation Strategy on Perioperative Functional Capability and Prognosis of Patients Undergoing Thoracoscopic Lobectomy for Lung Cancer：a Randomized Controlled Trail
Brief Summary: The process of enhancing an individual's functional capacity to optimize physiologic reserves before an operation to withstand the stress of surgery has been coined prehabilitation. This is a prospective randomized controlled trail, designed to explore if the patients who take thoracoscopic lobectomy for lung cancer will benefit from family trimodal prehabilitation strategy. Trimodal prehabilitation includes exercise, nutrition supplement and physiology management preoperatively. It starts from the day that patients decide to take the surgery until the day before surgery, lasting 2\~3 week in our hospital. And we follow-up patients until 8 weeks after surgery to investigate if trimodal prehabilitation strategy can improve the postoperative functional recovery，reduce complications and improve prognosis.


Options:
A: Arm Label: multimodal prehabilitation begun preop; Type: EXPERIMENTAL; Interventions: Behavioral: multimodal prehabilitation | Arm Label: Multimodal prehabilitation begun postop; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: multimodal prehabilitation | Intervention Type: BEHAVIORAL; Name: multimodal prehabilitation; Assigned to Arm(s): multimodal prehabilitation begun preop | Intervention Type: BEHAVIORAL; Name: multimodal prehabilitation; Assigned to Arm(s): Multimodal prehabilitation begun postop
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Standard nutrition counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Prehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Arm Label: Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Intervention Type: BEHAVIORAL; Name: Physical Exercise Program; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: DIETARY_SUPPLEMENT; Name: Whey Protein Isolate Powder; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: BEHAVIORAL; Name: Relaxation Techniques; Assigned to Arm(s): Prehabilitation, Rehabilitation
D: Arm Label: Prehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Trimodal prehabilitation management | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trimodal prehabilitation management; Assigned to Arm(s): Prehabilitation group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Trimodal Prehabilitation Strategy on Perioperative Functional Capability and Prognosis of Patients Undergoing Thoracoscopic Lobectomy for Lung Cancer：a Randomized Controlled Trail
Brief Summary: The process of enhancing an individual's functional capacity to optimize physiologic reserves before an operation to withstand the stress of surgery has been coined prehabilitation. This is a prospective randomized controlled trail, designed to explore if the patients who take thoracoscopic lobectomy for lung cancer will benefit from family trimodal prehabilitation strategy. Trimodal prehabilitation includes exercise, nutrition supplement and physiology management preoperatively. It starts from the day that patients decide to take the surgery until the day before surgery, lasting 2\~3 week in our hospital. And we follow-up patients until 8 weeks after surgery to investigate if trimodal prehabilitation strategy can improve the postoperative functional recovery，reduce complications and improve prognosis.


Options:
A: Arm Label: Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Rehabilitation Program | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation Program; Assigned to Arm(s): Rehabilitation Group
B: Arm Label: Physiotherapy; Type: EXPERIMENTAL; Interventions: Other: Physiotherapy | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physiotherapy; Assigned to Arm(s): Physiotherapy
C: Arm Label: Prehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Trimodal prehabilitation management | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trimodal prehabilitation management; Assigned to Arm(s): Prehabilitation group
D: Arm Label: rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation | Arm Label: usual care; Type: SHAM_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Rehabilitation; Assigned to Arm(s): rehabilitation | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sit-to-stand Test Use in Children and Adolescents With Cystic Fibrosis : Correlations With 6-Minute Walking Test, Quadriceps and Respiratory Muscle Strength and Health Related Quality of Life
Brief Summary: Cystic fibrosis (CF) is a chronic hereditary respiratory disease. Exercise testing is part of CF patients regular assessment.

Cardio-Pulmonary Exercise Testing (CPET) is currently considered as the gold standard to assess physical capacities. However, simple field tests are emerging. These tests are easier to perform especially in a population of CF children and adolescents.

The 1minute Sit-To-Stand test have recently been evaluated in CF adults. This test correlates with maximal oxygen consumption during CPET.

The investigators hypothesized that this test also correlates with 6-Minute Walking distance (during a 6-min Walk Test), quadriceps strength, respiratory muscles strength and health-related quality of life.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
B: Arm Label: 1. Exercise testing and self drainage session; Type: EXPERIMENTAL; Interventions: Procedure: Chest physiotherapy | Arm Label: 2. Chest physiotherapy (CP) session; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy; Assigned to Arm(s): 1. Exercise testing and self drainage session, 2. Chest physiotherapy (CP) session
C: Arm Label: Fitbit plus personalised text messaging & Goal Setting; Type: EXPERIMENTAL; Interventions: Other: Fitness tracker with goal setting and text message feedback | Arm Label: Fitbit Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Fitness Tracker only | Intervention Type: OTHER; Name: Fitness tracker with goal setting and text message feedback; Assigned to Arm(s): Fitbit plus personalised text messaging & Goal Setting | Intervention Type: OTHER; Name: Fitness Tracker only; Assigned to Arm(s): Fitbit Only
D: Arm Label: Sit-to-stand test; Type: EXPERIMENTAL; Interventions: Behavioral: Sit-to-stand test | Arm Label: 6-Minute Walk Test; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 6-Minute Walk Test | Intervention Type: BEHAVIORAL; Name: Sit-to-stand test; Assigned to Arm(s): Sit-to-stand test | Intervention Type: BEHAVIORAL; Name: 6-Minute Walk Test; Assigned to Arm(s): 6-Minute Walk Test

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial
Brief Summary: Postpartum hemorrhage (PPH) occurs in up to one in ten deliveries worldwide and is the leading cause of maternal morbidity and mortality. In developing countries 30% of women develop PPH because access to a number of treatments is not readily available. Interestingly, the rate of PPH and consequently of maternal morbidity has increased significantly even in developed nations, such as Canada, over the past decades. This rate is also increasing amongst parturients in Ontario. Unfortunately, few effective preventative treatments exist.

Antifibrinolytic drugs are routinely used to reduce bleeding and the requirement for blood transfusions in a wide range of hemorrhagic conditions. The most commonly used antifibrinolytic drug is tranexamic acid (TXA). TXA is safe, affordable, with very few side effects. The World Health Organization recommended that TXA be used to reduce blood loss in several conditions, including in patients with established PPH refractory to conventional therapy.However, little is known about the prophylactic use of TXA to prevent PPH.


Options:
A: Arm Label: Intravenous tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml | Arm Label: Intramuscular tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid Injectable Product | Arm Label: Oral liquid tranexamic acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid Oral Solution | Arm Label: No tranexamic acid; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml; Assigned to Arm(s): Intravenous tranexamic acid | Intervention Type: DRUG; Name: Tranexamic Acid Oral Solution; Assigned to Arm(s): Oral liquid tranexamic acid | Intervention Type: DRUG; Name: Tranexamic Acid Injectable Product; Assigned to Arm(s): Intramuscular tranexamic acid
B: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
C: Arm Label: TXA (1g); Type: EXPERIMENTAL; Interventions: Drug: TXA (1g) | Arm Label: Placebo (0.9% saline); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (0.9% saline) | Intervention Type: DRUG; Name: TXA (1g); Assigned to Arm(s): TXA (1g) | Intervention Type: DRUG; Name: Placebo (0.9% saline); Assigned to Arm(s): Placebo (0.9% saline)
D: Arm Label: Study group/Group A; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid injection | Arm Label: Control group/Group B; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal saline placebo | Intervention Type: DRUG; Name: Tranexamic acid injection; Assigned to Arm(s): Study group/Group A | Intervention Type: OTHER; Name: Normal saline placebo; Assigned to Arm(s): Control group/Group B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial
Brief Summary: The risk of venous thromboembolism (VTE) is very high in trauma patients, secondary to tissue injury, venous status from immobilization, and thrombophilia. As such, early initiation of VTE prophylaxis is essential in this population. The competing risks of life threatening hemorrhage and VTE need to be considered very carefully. Potential approaches to VTE prophylaxis include pharmacologic means, and mechanical devices. For patients unable to receive pharmacologic VTE prophylaxis, retrievable inferior vena cava filters (rIVCFs) may be placed until low molecular weight heparin (LMWH) can be initiated, as per guidelines such as Eastern Association for the Surgery of Trauma

The investigators propose a feasibility study to determine whether or not our center can insert rIVCFs in at-risk trauma patients expeditiously enough to cause a meaningful reduction in the time they are left unprotected to PE.


Options:
A: Arm Label: Patients undergoing Pulmonary Embolectomy; Type: N/A; Interventions: Procedure: Catheter directed debulking of Pulmonary Embolus | Intervention Type: PROCEDURE; Name: Catheter directed debulking of Pulmonary Embolus; Assigned to Arm(s): Patients undergoing Pulmonary Embolectomy
B: Arm Label: CDT without ultrasound acceleration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT without ultrasound acceleration | Arm Label: CDT ultrasound accelerated; Type: EXPERIMENTAL; Interventions: Procedure: CDT with ultrasound acceleration | Intervention Type: PROCEDURE; Name: CDT without ultrasound acceleration; Assigned to Arm(s): CDT without ultrasound acceleration | Intervention Type: PROCEDURE; Name: CDT with ultrasound acceleration; Assigned to Arm(s): CDT ultrasound accelerated
C: Arm Label: rIVCF; Type: EXPERIMENTAL; Interventions: Device: Cook 'Celect' retrievable inferior vena cava filter | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Cook 'Celect' retrievable inferior vena cava filter; Assigned to Arm(s): rIVCF
D: Arm Label: EkoSonic® Endovascular System; Type: EXPERIMENTAL; Interventions: Drug: recombinant tissue plasminogen activator, Device: EKOS EkoSonic Endovascular System | Intervention Type: DRUG; Name: recombinant tissue plasminogen activator; Assigned to Arm(s): EkoSonic® Endovascular System | Intervention Type: DEVICE; Name: EKOS EkoSonic Endovascular System; Assigned to Arm(s): EkoSonic® Endovascular System

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients With Resistant Hypertension and Chronic Kidney Disease
Brief Summary: The purpose of this study is to determine if patiromer treatment in chronic kidney disease (CKD) subjects receiving spironolactone for the treatment of resistant hypertension will result in more persistent use of spironolactone through prevention of hyperkalemia and lead to improved blood pressure control compared with treatment with spironolactone alone (placebo).


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Spironolactone; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Spironolactone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group 1 - Patiromer; Type: EXPERIMENTAL; Interventions: Drug: Patiromer, Drug: Spironolactone | Arm Label: Group 2 - Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Spironolactone | Intervention Type: DRUG; Name: Patiromer; Assigned to Arm(s): Group 1 - Patiromer | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2 - Placebo | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Group 1 - Patiromer, Group 2 - Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Eplerenone | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Drug: Eplerenone | Intervention Type: DRUG; Name: Eplerenone; Assigned to Arm(s): 1, 2
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 4; Type: EXPERIMENTAL; Interventions: Drug: BAY94-8862 | Arm Label: Arm 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Arm 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: BAY94-8862; Assigned to Arm(s): Arm 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 5 | Intervention Type: DRUG; Name: Spironolactone; Assigned to Arm(s): Arm 6

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of a New Protocol for Indirect Pulp Capping Procedures
Brief Summary: The aim of the study is to assess clinically, radiographically and microbiologically a new protocol for indirect pulp capping procedures compared to the conventional protocol in painful teeth. It was postulated that there is no difference between both protocols in terms clinical, radiographical and microbial outcome measure after one year of follow up in painful teeth.


Options:
A: Arm Label: Hall Technique; Type: EXPERIMENTAL; Interventions: Procedure: Hall Technique | Arm Label: Non-Restorative Caries Treatment; Type: EXPERIMENTAL; Interventions: Procedure: Non-Restorative Caries Treatment | Arm Label: Conventional Restoration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Restoration | Intervention Type: PROCEDURE; Name: Hall Technique; Assigned to Arm(s): Hall Technique | Intervention Type: PROCEDURE; Name: Non-Restorative Caries Treatment; Assigned to Arm(s): Non-Restorative Caries Treatment | Intervention Type: PROCEDURE; Name: Conventional Restoration; Assigned to Arm(s): Conventional Restoration
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: Mechanical rotary burs | Arm Label: Conservative; Type: EXPERIMENTAL; Interventions: Device: Carisolv gel | Intervention Type: DEVICE; Name: Mechanical rotary burs; Assigned to Arm(s): Control | Intervention Type: DEVICE; Name: Carisolv gel; Assigned to Arm(s): Conservative
C: Arm Label: SW intervention; Type: EXPERIMENTAL; Interventions: Procedure: SW | Arm Label: DCE intervention; Type: OTHER; Interventions: Procedure: DCE | Intervention Type: PROCEDURE; Name: SW; Assigned to Arm(s): SW intervention | Intervention Type: PROCEDURE; Name: DCE; Assigned to Arm(s): DCE intervention
D: Arm Label: Glass Ionomer Sealant; Type: EXPERIMENTAL; Interventions: Drug: Sealants to arrest microcavitated caries. | Arm Label: Resin Sealant; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sealants to arrest microcavitated caries. | Intervention Type: DRUG; Name: Sealants to arrest microcavitated caries.; Assigned to Arm(s): Glass Ionomer Sealant, Resin Sealant

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Maternal Docosa-Hexaenoic Acid (DHA) Supplementation and Offspring Neurodevelopment in India (DHANI-2)
Brief Summary: DHANI-2 is an extension to DHANI (NCT01580345) which proposes to extend maternal supplementation (DHA or Placebo) from \<20 weeks of gestational age through 6 months postpartum and infant follow-up through 12 months. Leveraging the Randomized Controlled Trial (RCT) design, DHANI-2 aims to assess the role of maternal DHA supplementation on infant neurodevelopment and body growth. It also intends to enhance the mechanistic understanding by the addition of repeated biochemical measures from mother-child dyads.


Options:
A: Arm Label: Dietary advice and grocery store card; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary advice | Arm Label: Dietary advice; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary advice | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Dietary advice; Assigned to Arm(s): Dietary advice, Dietary advice and grocery store card | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control
B: Arm Label: Docosa Hexaenoic Acid (DHA); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Docosa Hexaenoic Acid (DHA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Docosa Hexaenoic Acid (DHA); Assigned to Arm(s): Docosa Hexaenoic Acid (DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Fish-Oil; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Fish oil, Ocean plus | Arm Label: Sunflower oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sunflower Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish oil, Ocean plus; Assigned to Arm(s): Fish-Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Sunflower Oil; Assigned to Arm(s): Sunflower oil
D: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol

Answer: B